The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

Beyond improving accuracy, xAI allowed researchers to compare prognostic markers across different cancer types, unveiling ...

The NAACP is urging cancer be declared as a public health crisis in the Black community in response to troubling CDC research.

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Researchers have developed a groundbreaking AI model that identifies tumor-fighting immune cells, enhancing cancer ...

A recent editorial explores the effectiveness of complex risk models for lung cancer screening, suggesting that simpler ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

In this video, Xiuning Le, MD, PhD, discusses some of the latest developments in the study and treatment of EGFR-mutated lung cancer.